Skip to content

Venous Injection Compared To intraOsseous Injection During Resuscitation of Patients With Out-of-hospital Cardiac Arrest

Venous Injection Compared To intraOsseous Injection During Resuscitation of Patients With Out-of-hospital Cardiac Arrest (The VICTOR Trial)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04135547
Acronym
VICTOR
Enrollment
1732
Registered
2019-10-22
Start date
2020-07-06
Completion date
2023-06-30
Last updated
2023-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergency Medical Service, Intraosseous Access, Intravenous Access, Out-of-Hospital Cardiac Arrest, Vascular Access

Brief summary

Overall survival of patients after out-of-hospital cardiac arrest (\*OHCA\*) is less than 10% worldwide and in Taiwan. Interventions provided by the emergency medical system (\*EMS\*) before arrival at the hospital are of paramount importance to patient outcomes after OHCA. Among those interventions, the pros-and-cons of different vascular accesses, including intraosseous (\*IO\*) access or intravenous (\*IV\*) access, remained the issue of most under debate. The objective of this study is to determine the comparative effectiveness of IO access vs IV access in patients with OHCA by a randomized controlled trial (\*RCT\*) in Taipei EMS. To name in short, the investigators called it a \*VICTOR\* trial standing for Venous Injection Compared To intraOsseous injection during Resuscitation of patients with out-of-hospital cardiac arrest.

Detailed description

Overall survival of patients after out-of-hospital cardiac arrest (\*OHCA\*) is less than 10% worldwide and in Taiwan. Interventions provided by the emergency medical system (\*EMS\*) before hospital care is of paramount importance to patient outcomes after OHCA. Among those interventions, the pros and cons of different vascular accesses, including intraosseous (\*IO\*) access or intravenous (\*IV\*) access, recently became the focus under debate. Theoretically, IO access provides a rapidly established way to administrate medication and fluid to patients (Reference 1) and has been adopted in many acute care societies and organizations including current resuscitation guidelines (Reference 2). However, some of the recent publications questioned the outcomes of OHCA patients receiving the IO route comparing to the IV route (References 3-5). Studies showed non-different or negative outcomes of patients receiving the IO route has been severely biased through the inherent inadequacy of retrospective design (References 3-5). The three major problems of those studies were: 1. . Time to vascular access cannot be adjusted. In many EMS, IO access was allowed only after one or two failed attempts of IV route. This led to a significant selection bias. 2. . The location of vascular access was not accurately reported. As we know, medications through upper limbs arrive at the heart sooner than the lower limbs. Many paramedics tend to insert the IO needle in tibia but to inset IV catheters in the forearm vein. 3. . Post-hoc analysis with old data over 5 to 10 years. Two of the three studies were the post-hoc analysis from the data of previous studies which was conducted from 2007 to 2010 when cardiopulmonary resuscitation quality and teamwork (i.e. important confounding factors to OHCA survival) were not that emphasized and recorded. Hence, the investigators designed the study to determine the comparative effectiveness of IO access vs IV access in patients with OHCA by a randomized controlled trial (\*RCT\*) in Taipei EMS. In this 2-year research plan, we will conduct a prehospital RCT to address the following question: In adult patients with non-traumatic cause of OHCA resuscitated by emergency medical technician paramedic in the prehospital setting, will receiving IO access cause a better chance of survival to discharge, sustained recovery of spontaneous circulation, and other survival outcomes like neurologically favorable status, comparing to those who receiving IV access. To name in short, the investigators called it a \*VICTOR\* trial standing for Venous Injection Compared To intraOsseous injection during Resuscitation of patients with out-of-hospital cardiac arrest.

Interventions

DEVICEintra-osseous access vs. intra-venous access

EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures

Sponsors

Ministry of Science and Technology, Taiwan
CollaboratorOTHER_GOV
Teleflex
CollaboratorINDUSTRY
National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

The intervention (IO vs IV route) on the patients with out-of-hospital cardiac arrest can not be masked.

Intervention model description

randomized clinical trial

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Out-of-hospital cardiac arrest (OHCA) activated Taipei EMS ALS team (EMTP) * Adult ≥ 20 years old

Exclusion criteria

* OHCA patients with signs of obvious death, e.g. rigor mortis * Existing do-not-attempt-resuscitation order * Patients with cardiac arrest en route to the hospital * OHCA patients with successful vascular access before EMTP arrival * OHCA patients with a canceled ambulance call or being transported to the hospital before EMTP arrival * OHCA patients with known or suspected pregnancy * OHCA patients with traumatic cause of cardiac arrest * OHCA patients with known or suspected \< 20 years old, or \> 80 years old * OHCA patients with contraindications to IO access or IV access

Design outcomes

Primary

MeasureTime frameDescription
the rate of survival to hospital dischargeup to 1 month after the OHCA eventOHCA patients with survival to hospital discharge

Secondary

MeasureTime frameDescription
the time and rate of return of spontaneous circulation (*ROSC*)up to 1 week after the OHCA eventthe time and rate of return of spontaneous circulation (\*ROSC\*), prehospital ROSC
survival to admissionup to 1 week after the OHCA eventsurvival to admission, or in some overcrodwed hospital, surrogated by sustained ROSC \> 2hrs
favorable neurologic survival stausup to 1 month after the OHCA eventfavorable neurologic survival staus defined by CPC 1 & 2 level (CPC: cerebral performance categlory)

Other

MeasureTime frameDescription
subgroups analysisthrough study completion, an average of half a yearincluding subgroups with different ages, sexs, witnessed status, initial presenting rhythm (shockable vs. non-shockable), bystander CPR, response intervals, time to vascular access, and time to first-dose epinephrine.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026